Investment case
Health Care Select Sector SPDR Fund
XLV · 7 developments mapped · last assessed 2026-09-21
Market Ontology has mapped 7 macro, policy, and market developments to Health Care Select Sector SPDR Fund since 2026-09-15. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for XLV yet, so no modelled value is shown. The XLV valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run XLV on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
Strong performance of major pharmaceutical components, particularly Eli Lilly, driving overall sector growth and investor sentiment.
· Moves sector growth outlook, investor sentiment, risk premium
What changed, by assumption
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
- 2026-09-15Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend Demand
- 2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand Rises
- 2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive Rotation
- 2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue
- 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-21 | Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix | Bullish | 1-3m | 0.30 |
| 2026-09-21 | Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth | Bullish | 1-5d | 0.30 |
| 2026-09-21 | Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue | Bullish | 1-5d | 0.40 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage | Bullish | 1-3m | 0.70 |
| 2026-09-15 | Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend Demand | Bullish | 1-3m | 0.70 |
| 2026-09-15 | Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand Rises | Bullish | 1-3m | 0.60 |
| 2026-09-15 | Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive Rotation | Bullish | 1-3m | 0.60 |